Compare ELDN & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELDN | PALI |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.4M | 249.2M |
| IPO Year | 2014 | 2019 |
| Metric | ELDN | PALI |
|---|---|---|
| Price | $1.97 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $9.00 | $8.70 |
| AVG Volume (30 Days) | 918.4K | ★ 2.8M |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.67 | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $1.35 | $1.01 |
| 52 Week High | $4.49 | $2.86 |
| Indicator | ELDN | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 35.64 | 31.01 |
| Support Level | N/A | N/A |
| Resistance Level | $3.14 | $2.18 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 3.83 | 3.23 |
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.